ESMO 2024

September 13-17, 2024
Barcelona, Spain

European Society for Medical Oncology

Explore more Hematology-Oncology congress materials

Results(3)

Hematology-Oncology

516MO –Zanidatamab + Chemotherapy in First-Line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced/Metastatic Colorectal Cancer (CRC)

Author(s): Sun Young Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea

Hematology-Oncology

View Oral Presentation

HERIZON-BTC-302: A Phase 3 Study of Zanidatamab With Standard-of-Care Therapy vs Standard-of-Care Alone For First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Positive Advanced/Metastatic Biliary Tract Cancer

Author(s): Teresa Macarulla, Vall d’Hebrón University Hospital, Vall d´Hebrón Institute of Oncology, Barcelona, Spain

Hematology-Oncology

Zanidatamab + Chemotherapy for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastro-Oesophageal Adenocarcinoma: New and Updated Data From a Phase 2 Trial

Author(s): Elena Elimova, Princess Margaret Cancer Centre, Toronto, ON, Canada

Hematology-Oncology

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.